| Leighann Fullagar, APRN-CNS | |
|
3300 Nw Expressway, Oklahoma City, OK 73112-4418 | |
| (405) 713-7403 | |
| (405) 713-2794 |
| Full Name | Leighann Fullagar |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 5 Years |
| Location | 3300 Nw Expressway, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063065845 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2100X | Clinical Nurse Specialist - Acute Care | 76400 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Integris Baptist Medical Center, Inc | Oklahoma city, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Integris Ambulatory Care Corporation | 2365408465 | 382 |
News Archive
The Samuel Lunenfeld Research Institute's Drs. Frank Sicheri, Tony Pawson and Sebastian Guettler, in collaboration with Dr. Robert Rottapel at the Ontario Cancer Institute, have uncovered the detailed architecture of a crucial component of Tankyrase, a protein linked to the bone development disorder cherubism and involved in a myriad of cellular processes.
ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, provides an update on its development plans to broaden the scope of its lead product ERYASP into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer.
In this post in her Global Health Blog, Guardian Health Editor Sarah Boseley examines the potential impact of reform within the Global Fund to Fight AIDS, Tuberculosis and Malaria on the organization's future. She writes, "It's been only seven weeks since banker Gabriel Jaramillo took over as general manager of the fund, but it is already clear the worthy organization set up by Kofi Annan to channel money to treat and prevent diseases in poor countries is a leaner, meaner machine."
AccuVein LLC, the developer of the first non-contact, handheld vein illumination system, announced today that it had been awarded the maximum grant amount from the Qualifying Therapeutic Discover Project (QTDP) program. This Federal grant program supports projects that show significant potential to produce new therapies, address unmet medical needs, and reduce the long-term growth of health care costs.
› Verified 1 days ago
| Entity Name | Integris Ambulatory Care Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750333936 PECOS PAC ID: 2365408465 Enrollment ID: O20041209000354 |
News Archive
The Samuel Lunenfeld Research Institute's Drs. Frank Sicheri, Tony Pawson and Sebastian Guettler, in collaboration with Dr. Robert Rottapel at the Ontario Cancer Institute, have uncovered the detailed architecture of a crucial component of Tankyrase, a protein linked to the bone development disorder cherubism and involved in a myriad of cellular processes.
ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, provides an update on its development plans to broaden the scope of its lead product ERYASP into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer.
In this post in her Global Health Blog, Guardian Health Editor Sarah Boseley examines the potential impact of reform within the Global Fund to Fight AIDS, Tuberculosis and Malaria on the organization's future. She writes, "It's been only seven weeks since banker Gabriel Jaramillo took over as general manager of the fund, but it is already clear the worthy organization set up by Kofi Annan to channel money to treat and prevent diseases in poor countries is a leaner, meaner machine."
AccuVein LLC, the developer of the first non-contact, handheld vein illumination system, announced today that it had been awarded the maximum grant amount from the Qualifying Therapeutic Discover Project (QTDP) program. This Federal grant program supports projects that show significant potential to produce new therapies, address unmet medical needs, and reduce the long-term growth of health care costs.
› Verified 1 days ago
| Entity Name | Zuhdi Transplant Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942242623 PECOS PAC ID: 6507873403 Enrollment ID: O20060317000435 |
News Archive
The Samuel Lunenfeld Research Institute's Drs. Frank Sicheri, Tony Pawson and Sebastian Guettler, in collaboration with Dr. Robert Rottapel at the Ontario Cancer Institute, have uncovered the detailed architecture of a crucial component of Tankyrase, a protein linked to the bone development disorder cherubism and involved in a myriad of cellular processes.
ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, provides an update on its development plans to broaden the scope of its lead product ERYASP into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer.
In this post in her Global Health Blog, Guardian Health Editor Sarah Boseley examines the potential impact of reform within the Global Fund to Fight AIDS, Tuberculosis and Malaria on the organization's future. She writes, "It's been only seven weeks since banker Gabriel Jaramillo took over as general manager of the fund, but it is already clear the worthy organization set up by Kofi Annan to channel money to treat and prevent diseases in poor countries is a leaner, meaner machine."
AccuVein LLC, the developer of the first non-contact, handheld vein illumination system, announced today that it had been awarded the maximum grant amount from the Qualifying Therapeutic Discover Project (QTDP) program. This Federal grant program supports projects that show significant potential to produce new therapies, address unmet medical needs, and reduce the long-term growth of health care costs.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Leighann Fullagar, APRN-CNS 5300 N Independence Ave Ste 280, Oklahoma City, OK 73112-5555 Ph: (405) 713-7403 | Leighann Fullagar, APRN-CNS 3300 Nw Expressway, Oklahoma City, OK 73112-4418 Ph: (405) 713-7403 |
News Archive
The Samuel Lunenfeld Research Institute's Drs. Frank Sicheri, Tony Pawson and Sebastian Guettler, in collaboration with Dr. Robert Rottapel at the Ontario Cancer Institute, have uncovered the detailed architecture of a crucial component of Tankyrase, a protein linked to the bone development disorder cherubism and involved in a myriad of cellular processes.
ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, provides an update on its development plans to broaden the scope of its lead product ERYASP into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer.
In this post in her Global Health Blog, Guardian Health Editor Sarah Boseley examines the potential impact of reform within the Global Fund to Fight AIDS, Tuberculosis and Malaria on the organization's future. She writes, "It's been only seven weeks since banker Gabriel Jaramillo took over as general manager of the fund, but it is already clear the worthy organization set up by Kofi Annan to channel money to treat and prevent diseases in poor countries is a leaner, meaner machine."
AccuVein LLC, the developer of the first non-contact, handheld vein illumination system, announced today that it had been awarded the maximum grant amount from the Qualifying Therapeutic Discover Project (QTDP) program. This Federal grant program supports projects that show significant potential to produce new therapies, address unmet medical needs, and reduce the long-term growth of health care costs.
› Verified 1 days ago
Jamie Louise Hunt, APRN-CNS Clinical Nurse Specialist Medicare: Medicare Enrolled Practice Location: 800 Stanton L Young, Andrews Academic Tower, Suite 8400, Oklahoma City, OK 73104 Phone: 405-271-6173 Fax: 405-271-5892 | |
Mrs. Janet Elizabeth Kristic, APRN CLINICAL NURSE Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 1117 Nw 50th, Oklahoma City, OK 73118 Phone: 405-842-4435 Fax: 405-842-2846 | |
Todd J Ramer, CNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 4300 W Memorial Rd, Oklahoma City, OK 73120 Phone: 405-752-3539 | |
Andrea Jeanne Mccoy, R.N. Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 4050 W Memorial Rd, Oklahoma City, OK 73120 Phone: 405-608-3800 Fax: 405-608-3838 | |
Shanelle Stensaas, APRN-CNS Clinical Nurse Specialist Medicare: Medicare Enrolled Practice Location: 3300 Nw Expressway, Oklahoma City, OK 73112 Phone: 405-613-3351 | |
Michelle Tull, ACNS-BC Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 800 Ne 10th St, Oklahoma City, OK 73104 Phone: 405-271-3402 |